Volastra Therapeutics
New York, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $60M
Overview
An oncology biotech developing therapies that target cancers with high chromosomal instability.
OncologyGenetics & Genomics
Technology Platform
A discovery platform that identifies synthetic lethal vulnerabilities specific to cancers with high chromosomal instability (CIN).
Funding History
1Total raised:$60M
Series A$60M
Opportunities
Potential to develop a new class of targeted therapies for aggressive, metastatic cancers that are poorly served by existing treatments.
Risk Factors
Biological risk that CIN-targeting therapies may not achieve sufficient therapeutic index or face rapid acquired resistance.
Competitive Landscape
Occupies a novel niche in oncology by targeting chromosomal instability, competing with broader DNA damage response and synthetic lethality-focused companies.